$CDLX

Lynton Nicholas Hollmeyer sold $9K of CDLX

Lynton Nicholas Hollmeyer (Chief Legal & Privacy Officer) sold 2,151 shares of Cardlytics, Inc. (CDLX) at $4.40 on 2026-07-02.

Original reporting
SEC EDGAR · Lynton Nicholas Hollmeyer
Published Jul 6, 2026, 9:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CDLX
Neutral
high confidence
Mentioned
$CDLX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDLXNeutralLow
01

Why it matters

The disclosure provides confirmation of an officer’s open-market sale but does not include any new company performance, guidance, legal/regulatory, or deal information.

02

Market read

Primarily a sentiment/positioning datapoint; likely limited trading impact given small transaction size and lack of fundamental catalysts.

03

What to watch

Insider sales can be driven by taxes, diversification, or pre-planned personal liquidity; without additional context, the signal-to-noise for trading is low.

Relevance 3/10Novelty 2/10Timing: Filed 2026-07-06; reflects sale executed 2026-07-02.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Cardlytics, Inc.

Company-level read

Ticker impact

$CDLXNeutralHigh confidence
Context

Form 4 shows Cardlytics’ Chief Legal & Privacy Officer sold 2,151 shares on 2026-07-02 at $4.3950 for $9,453.64.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived.

Evidence & confidence

The filing is a small, non-10b5-1 sale by an officer with limited disclosed economic significance versus company size, and no new company-specific operational/regulatory catalyst is provided.

Market effects

No clear sector read-through; this is an isolated insider transaction with no accompanying guidance or regulatory development.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a near-term liquidity need or reduced confidence, but the disclosed value is modest.

Key entities

  • Cardlytics, Inc.

    Subject of the Form 4 insider transaction; ticker CDLX.

  • Lynton Nicholas Hollmeyer

    Chief Legal & Privacy Officer who sold 2,151 shares on 2026-07-02.

Related articles

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$CDLXMed

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdlx_form8-kx2026q2xex991.htm EX-99.1 Document Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Con